LongevityLeak

NAD+ precursor therapy

Nicotinamide Riboside (NR)

NR consistently raises NAD+ in humans, but downstream metabolic and performance outcomes vary by population and protocol.

Evidence Level B

Evidence and Risk Labels

Evidence A/B/C reflects research maturity, and risk levels reflect monitoring needs. These labels support comparison, not diagnosis or treatment decisions.

See full scoring guide

Clinical Snapshot

Effect Size
Reliable NAD+ elevation with context-dependent functional effects
Safety
Low Risk

Benefits appear context-dependent.

Research Dosing

This reflects common ranges and protocols used in published studies, not personal medical advice.

Typical Daily Dose
250-1000 mg
Timing
Morning with food or split dosing
Protocol Duration in Studies
6-12 weeks in common intervention studies

Higher ranges are typically used in metabolic/endurance protocols under supervision.

Best Fit Profiles

  • NAD precursor alternatives

Source Links